Her2 Receptor Antagonists - Biotech, Pharma and Life Science Channel
Targeted treatment of Her2-positive breast cancer with the anti-Her2 antibody trastuzumab has become an example of successful personalized medicine. The commercial success of Herceptin (trastuzumab) with 2008 sales US$ 4.8 bln and the development of resistance to trastuzumab treatment has spurred the discovery and development of efficacy enhanced versions of anti-Her2 antibodies or antibodies binding to an epitope different from that of trastuzumab. Other approaches include the development of therapeutic vaccines to specifically stimulate the immune system against Her2 positive cancer cells. Her2 receptor tyrosine kinase inhibitors with a broader target profile including other members of the Her receptor family or including other targets are also in development. More than 20 new molecular entities targeting Her2 are in clinical development up to phase III including vaccines, cells, proteins, antibodies and small molecules.
Add the Her2 Receptor Antagonists News Channel to your RSS reader;
News Articles
Novartis International AG / Novartis drug Afinitor® significantly extended time without disease progression in women with HER2 positive advanced breast cancer . Processed and transmitted by Thomson...
Puma Biotechnology Comment on Trading Activity
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, has been contacted by the New York Stock Exchange regarding today’s trading in the Company...
Additional macitentan (Opsumit) data in pulmonary arterial hypertension presented at ATS
Actelion Pharmaceuticals Ltd / Additional macitentan (Opsumit) data in pulmonary arterial hypertension presented at ATS . Processed and transmitted by Thomson Reuters ONE. The issuer is solely respo...
QUEBEC CITY, May 16, 2013 /PRNewswire/ -- Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of novel, proprietary compounds that target cholinergic receptors fo...
Medigene AG / Medigene publishes final results from phase II Investigator Initiated Trial of EndoTAG®-1 at ASCO 2013 . Processed and transmitted by Thomson Reuters ONE. The issuer is solely respons...
TUSTIN, CA -- (Marketwired) -- 05/16/13 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and dia...
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced scheduled presentations at the 2013 American Society for Clinical Oncology (ASCO) Annual Meeting, which is taking place...
RIDGEFIELD, Conn., May 15, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced the upcoming presentation of data from 14 abstracts involving three of th...
Idera Pharmaceuticals Reports First Quarter 2013 Financial Results
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today reported financial results for the quarter ended March 31, 2013. “Our next objective in Idera’s autoimmune dis...
Tokai Pharmaceuticals Announces $35.5 Million Series E Financing
Financing Reflects Encouraging Clinical Progress with Galeterone in Prostate Cancer Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developin...
Events
6TH ANNUAL RECOMBINANT ANTIBODIES Conference
An insight into novel therapeutics and future technologies
Companies
Tokai Pharmaceuticals is a U.S. biopharmaceutical company focused on developing new treatments for prostate cancer. The companyâs lead drug candidate, TOK-001, is the first i...
Izun Pharmaceuticals Corporation
Izun Pharmaceuticals is a US based pharmaceutical company with a wholly owned R&D center in Israel. Izunâs technology platform allows it to develop botanical drugs by optimiz...
Puma Biotechnology, Inc. is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company...
Cellmid is an Australian biotechnology company developing innovative novel therapies and diagnostic tests for inflammatory diseases, heart attack and cancer. Cellmid holds the lar...
Opsona is a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of majo...
Tokai Pharmaceuticals is a U.S. biopharmaceutical company focused on developing new treatments for prostate cancer. The companyâs lead drug candidate, galeterone (TOK-001), i...
EnVivo Pharmaceuticals, Inc. and its subsidiaries (âEnVivo Pharmaceuticalsâ or âEnVivoâ) are dedicated to discovering and developing small molecule therapeutic...
bioTheranostics discovers, develops, and commercializes a growing array of molecular diagnostic tests for cancer patients. Leveraging its unique expertise in expression profiling...
Opsona is a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of majo...
Trevena, Inc. is a leader in the discovery and development of GPCR biased ligand drugs. Trevena combines a powerful and efficient drug discovery platform with extensive developmen...
Clinical Trials
RATIONALE: Aromatase inhibitors, such as letrozole, prevent the formation of estradiol, a female hormone. Giving letrozole together with goserelin, leuprolide, or surgery may be an effecti...
89Zr-trastuzumab PET for Imaging the Effect of HSP90 Inhibition
HSP90 inhibition is a potentially new targeted drug modality in the treatment of HER2 positive, trastuzumab refractory breast cancer. Little is known about the pharmacodynamics of HSP90 in...
In this open-label multicenter trial patients with operable or locally advanced breast cancer will be randomized to pre-operative treatment with 8 cycles of chemotherapy (docetaxel followe...
Usefulness of Myocardial Deformation Imaging for Trastuzumab-induced Cardiotoxicity
Trastuzumab prolongs survival in patients with human epidermal growth factor receptor type 2-positive breast cancer. Sequential left ventricular (LV) ejection fraction (EF) assessment has...
Antithrombotic Triple Therapy in Humans
Background:The acute coronary syndrome (ACS) is a complication of coronary artery disease (CAD) and associated with increased mortality. Dual antiplatelet therapy of acetylsalicylic acid (...
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
HER2 gene amplification increases VEGF production in breast cancers; combined inhibition of HER2 and VEGF enhances response in xenograft models. The upregulation of VEGF in HER2-overexpres...
D-Serine Monotherapy for Schizophrenia
N-methyl-D-aspartate receptor (NMDAR) agonist, added to classical or atypical antipsychotic medication, has reduced negative, depressive, and cognitive symptomatology. We will be investiga...
D-Serine Adjuvant Treatment for Parkinson's Disease
The proposed experiment will evaluate the effects of the NMDA receptor full agonist D-serine (~2g/day) on persistent symptoms of Parkinson's Disease and on antiparkinsonian drugs-induced d...
The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria
An open labelled trial of Kineret (anakinra) induction therapy (100mg./day) in over a four week period in the treatment of Familial Cold Urticaria. Familial Cold Urticaria (FCU) is a rare...
Adenoscan® (adenosine) is an approved pharmacological stress agent indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. Th...
PubMed Articles
p73 gene shares structural and functional similarities to p53 and plays an important role in modulating cell cycle arrest and apoptosis. A common non-coding polymorphism of p73 G4C14-to-A4T14 (rs22739...
P2Y12 receptor inhibition augments cytotoxic effects of cisplatin in breast cancer.
Expression of P2Y12 receptors has been documented in some cancer cell lines like C6 glioma, renal carcinoma and colon carcinoma. However, its direct role in altering response to chemotherapeutics has...
Prostate cancer (PCa) is one of the most commonly diagnosed malignancies in men and the second leading cause of male cancer mortality. MAZ (Myc-associated zinc-finger protein) is a transcription facto...
AIMS/HYPOTHESIS: The nuclear receptor peroxisome proliferator-activated receptor gamma (PPARγ) is an important gene regulator in glucose and lipid metabolism. Unfortunately, PPARγ-activating drugs o...
Apoptosis can occur throughout the life span of osteoblasts (OBs), beginning from the early stages of differentiation and continuing throughout all stages of their working life. Here, we investigated...
Treatment strategies for gastric cancer patients with peritoneal metastasis.
Although the treatment of gastric cancer improves the clinical outcomes, the survival of gastric cancer patients with peritoneal metastasis is still very poor. Effective drugs against peritoneal metas...
Bcl10 is an essential regulator for A20 gene expression.
A20, a tumor suppressor in several types of lymphomas, has been suggested to be an nuclear factor kappa B (NF-κB) target gene; conversely, the deubiquitylation activity of A20 is required for inhibit...
Integrin β4 and its Y-1494 phosphorylation play an important role in cell signaling. We found a small molecule, ethyl1-(3-(4-chlorophenoxy)-2-hydroxypropyl)-3-(4-chlorophenyl)-1H-pyrazole-5-carboxyla...
INTRODUCTION: Neuroectodermal tumors in general demonstrate high and dense expression of the somatostatin receptor subtype 2 (sst2). It controls proliferation of both normal and neoplastic cells. sst2...
Structure of the human smoothened receptor bound to an antitumour agent.
The smoothened (SMO) receptor, a key signal transducer in the hedgehog signalling pathway, is responsible for the maintenance of normal embryonic development and is implicated in carcinogenesis. It is...
Videos
VEGF and EGFR pathways in detail: Target for new therapies against cancer
Mechanism of action of VEGF (vascular endothelial growth factor) and EGFR (epidermal growth factor receptor) signalling pathways. Mécanisme d'action des voie...
Medical and Biotech [MESH] Definitions
Transferrin-binding Protein A
A subtype of bacterial transferrin-binding protein found in bacteria. It forms a cell surface receptor complex with TRANSFERRIN-BINDING PROTEIN B.
Transferrin-binding Protein B
A subtype of bacterial transferrin-binding protein found in bacteria. It forms a cell surface receptor complex with TRANSFERRIN-BINDING PROTEIN A.
Bacterial Transferrin Receptor Complex
A complex of proteins that forms a receptor for TRANSFERRIN in BACTERIA. Many pathogenic bacteria utilize the transferrin-binding complex to acquire their supply of iron from serum.
Receptors, Eph Family
A large family of receptor protein-tyrosine kinases that are structurally-related. The name of this family of proteins derives from original protein Eph (now called the EPHA1 RECEPTOR), which was named after the cell line it was first discovered in: Erythropoietin-Producing human Hepatocellular carcinoma cell line. Members of this family have been implicated in regulation of cell-cell interactions involved in nervous system patterning and development.
Receptor, Epha1
The founding member of the EPH FAMILY RECEPTORS. It was first cloned from an erythropoietin-producing human hepatocellular carcinoma cell line and is highly conserved among many mammalian species. Overproduction of the EphA1 receptor is associated with tumors and tumor cells of epithelial origin. It is also expressed at high levels in LIVER; LUNG; and KIDNEY; which is in contrast to many other members of the Eph receptor that are found primarily in tissues of the nervous system.
